Journal
CYTOKINE & GROWTH FACTOR REVIEWS
Volume 25, Issue 3, Pages 317-325Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2014.04.002
Keywords
Atherosclerosis; Chemokine; Chronic kidney disease; Inflammation
Categories
Funding
- FIS [PS09/00447, PI13/00047]
- ISCIII-RETIC [REDinREN/RD06/0016, REDinREN/RD12/0021]
- Comunidad de Madrid [S2010/BMD-2378]
- Sociedad Espanola de Nefrologia
- ISCIII Sara Borrell
- ISCIII Rio Hortega
- Swedish Research Council
Ask authors/readers for more resources
CXC chemokine ligand 16 (CXCL16) is a CXC soluble chemokine, an adhesion molecule and a cell surface scavenger receptor. CXCL16 regulates inflammation, tissue injury and fibrosis. Parenchymal renal cells, vascular wall cells, leukocytes and platelets express and/or release CXCL16 under the regulation of inflammatory mediators. CXCL16 expression is increased in experimental and human nephropathies. Targeting CXCL16 protected from experimental glomerular injury or interstitial fibrosis. Conflicting results were reported for experimental cardiovascular injury. High circulating CXCL16 levels are associated to human kidney and cardiovascular disease and urinary CXCL16 may increase in kidney injury. In conclusion, mounting evidence suggests a role of CXCL16 in kidney and cardiovascular disease. However, a better understanding is still required before exploring CXCL16 targeting in the clinic. (C) 2014 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available